ClinicalTrials.Veeva

Menu

Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections (DALBASAT)

T

Tourcoing Hospital

Status

Completed

Conditions

Prosthesis-related Infections

Treatments

Drug: Dalbavancin Injection

Study type

Observational

Funder types

Other

Identifiers

NCT06089044
CHT/URC/2023/12

Details and patient eligibility

About

The aim of this retrospective observational study is to evaluate the efficacy of antibiotic therapy with dalbavancin in patients presenting with infection on prosthetic devices. The main questions the study aims to answer are:

What is the proportion of patients with early discontinuation of dalbavancin therapy? What are the reasons for early discontinuation of antibiotic treatment? What adverse events do patients report? The study is based on data collected as part of routine care practices.

Translated with www.DeepL.com/Translator (free version)

Enrollment

15 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with inextricable and/or inoperable osteoarticular or vascular prosthetic material.
  • Patients requiring suppressive antibiotic therapy (>6 months) with dalbavancin.

Exclusion criteria

  • Patients who are protected adult;
  • Patients who are minors;
  • Patients having expressed their opposition

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems